30 closest matches · ranked by relevance
Methicillin Resistant Staphylococcus Aureus (MRSA)
Primary: Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population — 95; 81; 70; 93 Participants…
Pneumonia Due to Staphylococcus Aureus
Primary: Efficacy Endpoint: All-Cause Mortality by Day 28 — 1; 2; 2; 0 Participants
Pneumonia
Primary: Time to 30-day Mortality — 15; 14 days
Methicillin-Resistant Staphylococcus Aureus (MRSA) · Hospital-Acquired Pneumonia
Primary: Percentage of Participants With Clinical Success — 85; 69 percentage of participants — p=0.009
Staphylococcus Aureus Pneumonia
Primary: Percentage of Participants With Endpoint Adjudication Committee-Determined (EAC) Staphylococcus Aureus (S Aureus) Pneumonia — 26.0; 20.0; 17.7 Percentage of Participants…
Bacteremia · Staphylococcus Aureus · Staphylococcus Aureus Bacteremia
Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) Following Multiple Doses of Intravenous AP-Sa02. — 17; 10; 6; 2 number of…
Healthcare Associated Pneumonia
Primary: Pathogens of Healthcare Associated Pneumonia, Measured by the Number of Participants — 15; 51; 195; 269 Participants
Bacterial Pneumonia
Primary: Clinical Response — 214; 221; 46; 68 participants
Pseudomonas Aeruginosa Pneumonia
Primary: Clinical Cure on Day 21 — 34; 37; 6; 5 Participants — p=0.6154
Infections
Primary: Clinical Response at Study Day 4 in the Modified Intent-to-Treat (MITT) Population — 14; 8; 16; 8 participants
Bacterial Pneumonia
Primary: Clinical Response — 227; 228; 53; 52 participants
Cystic Fibrosis
Primary: Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture — 2; 3 Participants
Staphylococcus Aureus Bacteremia
Primary: Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit — 132; 136; 57; 62 Participants
Pneumonia
Primary: Number of Patients With Modified Diagnosis Probability After Low Dose CT (LDCT) — 10; 3; 4; 34 Participants
Atopic Dermatitis
Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score
Community-acquired Pneumonia (CAP) · Hospital-acquired Pneumonia (HAP)
Primary: Adverse Events — 10; 5; 1; 0 Participants
Wound Infection Due to Staphylococcus Aureus · MRSA Infection of Postoperative Wound
Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants
Pneumonia, Bacterial
Primary: Number of Participants Surviving Through LFU Visit — 191; 196; 64; 57 Participants — p=0.4263
Community-acquired Pneumonia
Primary: Vancomycin-free Hours Alive — 105.7; 109.7 Hours
Pseudomonas Aeruginosa
Primary: Percentage of Participants With Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa — 18.1; 12.5; 22.4 Percentage of participants — p=0.491
Osteomyelitis
Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants
MRSA Colonization
Primary: Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays — 96.6 percentage of participants
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Carriage of Streptococcus Pneumoniae in Nasopharynx — 12.6 Percentage of Participants
Community Acquired Respiratory Disease Syndrome
Primary: 60-day Mortality — 50; 47; 227; 239 Participants — p=0.635
Staphylococcus Aureus Bacteremia
Primary: Number of Participants Who Experienced Dose-limiting Toxicities — 0; 0; 0; 0 participants
MRSA · Cystic Fibrosis
Primary: Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted — 2.39; 1.18; 1.52; 0.13 Percent predicted — p=0.325
Nasal Carriers of Staphylococcus Aureus
Primary: Carrier Rate for Staphylococcus Aureus — 20.8 percentage of subjects
Staphylococcus Aureus Bacteremia · Staphylococcus Aureus Endocarditis
Primary: Incidence of Adverse Events [Safety and Tolerability] — 48; 30; 64; 40 Participants
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
Community Acquired Pneumonia
Primary: Early Clinical Response (ECR) — 241; 248; 29; 21 Participants